Cargando…

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data

Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from −0.78% to −1.64% over 52–104 weeks, and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kugler, Anne J, Thiman, Michael L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951211/
https://www.ncbi.nlm.nih.gov/pubmed/29780260
http://dx.doi.org/10.2147/DMSO.S134960